Endocrinología

A continuación, se enumeran los ensayos clínicos actuales.

Filtra esta lista de estudios por sede, estatus, etc.

1. A Study to Evaluate How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease

   Rochester, Minn.

   The purpose of this study is to evaluate whether or not semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will receive semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer.

2. A Study of Immune Cell Abnormalities Found in Individual Patients who have Type 1 Diabetes and are Waiting for Pancreas or Pancreas/Kidney Transplant Surgery

   Rochester, Minn.

   The purpose of this study is to measure and characterize specific immune cell abnormalities found in patients who have type 1 diabetes and may or may not be on the waiting list for either a pancreas alone or a pancreas and kidney transplant.

3. A Study to Evaluate the Therapeutic Effectiveness of Rifaximin in Diabetic Gastroparesis Patients Using Bloating as the Primary Endpoint

   Jacksonville, Fla.

   The primary purpose of this study is to prospectively assess symptoms of bloating (severity, prevalence) in patients with diabetic gastroparesis.

4. A Study to Evaluate Pemetrexed and Pembrolizumab to Treat Recurrent and/or Metastatic Salivary Gland Malignancies

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine the response rate of the combination of Pemetrexed and Pembrolizumab in patients with recurrent or metastatic salivary gland cancer (R/M SGC).

5. To Assess the Effectiveness, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

   Rochester, Minn.

   The purpose of this study is to evaluate the effectiveness, safety, tolerability, and PK of INCB000928 over a 24-week treatment period followed by a 52-week, open-label extension period.

6. Risk and Benefit Assessment of Pancreas Transplantation

   Rochester, Minn.

   The purpose of this study is to (i)assess glucose variability at pre specified time points after Pancreas Transplantation (ii) collect pre-specified serious adverse events after PT and in appropriate control groups (iii) assess mixed meal dynamics after pancreas transplantation.

7. Prospective Study of Adrenal Disorders: Clinical Registry, Imaging Analysis and Biomaterial Collection

   Rochester, Minn.

   The purpose of this research is to follow people with adrenal disorders in order to make conclusions about the natural history of a particular adrenal disease as well as effect of various therapies and interventions decided on by you and your medical team. In addition, we will collect biomaterial from you at times you are being evaluated which will be used to discover novel biomarkers which can potentially improve the accuracy of current diagnostic tests and affect the management of patients with adrenal disorders. We will also include a control group (without known adrenal disease) to compare to the volunteers with adrenal disorders.

8. Feasibility of a Constant Pressure Skin Disk (CPSD) in Enteral Tubes

   Rochester, Minn.

   The purpose of this research study is to gather information on one specific part of a feeding tube, known as the adjustable skin disk. The goal of this research study is to see if a new type of adjustable skin disk, called a Constant Pressure Skin Disk (CPSD), can safely and effectively support one or more of the following: 1) adequate healing after feeding tube placement; 2) a reduced rate of complications associated with feeding tubes, such as leakage, skin breakdown, etc.; 3) ease of use; and 4) durability (holds up to usual wear and tear associated with feeding tube use).

9. Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 1

   Scottsdale/Phoenix, Ariz.

   This study is being done to better understand the relationship between inflammation in your AT, abnormal deposition of fat around your liver and how this affects its appearance and function and ultimately insulin resistance.

10. Intramyocellular Fatty Acid Trafficking in Insulin Resistance States - Effects of Intestinal Delivery of Lipids

    Rochester, Minn.

    Muscle insulin resistance is a hallmark of upper body obesity (UBO) and Type 2 diabetes (T2DM). It is unknown whether muscle free fatty acid (FFA) availability or intramyocellular fatty acid trafficking is responsible for muscle insulin resistance, although it has been shown that raising FFA with Intralipid can cause muscle insulin resistance within 4 hours. We do not understand to what extent the incorporation of FFA into ceramides or diacylglycerols (DG) affect insulin signaling and muscle glucose uptake. We propose to alter the profile and concentrations of FFA of healthy, non-obese adults using an overnight, intra-duodenal palm oil infusion vs. an intra-duodenal Intralipid infusion (both compared to saline control). We will compare the muscle FFA storage into intramyocellular triglyceride, intramyocellular fatty acid trafficking, activation of the insulin signaling pathway and glucose disposal rates, providing the first measure of how different FFA profiles alter muscle FFA trafficking and insulin action at the whole body and cellular/molecular levels. By identifying which steps in the insulin signaling pathway are most affected, we will determine the site-specific effect of ceramides and/or DG on different degrees of insulin resistance.
    Hypothesis 1: Palm oil infusion will result in abnormal FFA trafficking into intra-myocellular ceramides and abnormal insulin signaling.
    Hypothesis 2: Intralipid infusion will result in abnormal FFA trafficking into intra-myocellular saturated DG and abnormal insulin signaling.